for Journals by Title or ISSN
for Articles by Keywords
help
Followed Journals
Journal you Follow: 0
 
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Journals are published.
Already have an account? Sign In to see the journals you follow.
Journal Cover The Medical Letter
  [SJR: 0.142]   [H-I: 16]   [5 followers]  Follow
    
   Full-text available via subscription Subscription journal
   ISSN (Print) 0025-732X - ISSN (Online) 1523-2859
   Published by The Medical Letter, Inc Homepage  [1 journal]
  • Addendum: Cannabis and Cannabinoids
    • Authors: admin
      Abstract: Date:  August 29, 2016 Issue #:  1502 Summary:  A reader asked why our Cannabis and Cannabinoids article (Med Lett Drugs Ther 2016; 58:97) did not include our usual Dosage/Cost table. We have now posted one in the article as it appears online. You can access it here: www.medicalletter. org/TML-article-1500a.

      Download complete U.S. English article


      PubDate: Tue, 16 Aug 2016 16:44:20 +000
       
  • Sugammadex (Bridion) for Rapid Reversal of Neuromuscular Blockade
    • Authors: admin
      Abstract: Date:  August 29, 2016 Issue #:  1502 Summary:  The FDA has approved sugammadex (Bridion – Merck), a selective relaxant binding agent, for reversal of rocuronium- or vecuronium-induced neuromuscular blockade in adult surgical patients. It is the first selective relaxant binding agent to be approved in the US. Sugammadex has been available in the European Union, Japan, and elsewhere for several years. Previous FDA reviews of sugammadex did not result in approval because of concerns about a risk of anaphylaxis and other hypersensitivity reactions with its use.
      PubDate: Wed, 10 Aug 2016 11:28:38 +000
       
  • An Oral Cholera Vaccine for Travelers (Vaxchora)
    • Authors: admin
      Abstract: Date:  August 29, 2016 Issue #:  1502 Summary:  The FDA has approved Vaxchora (PaxVax), a single-dose, oral, live-attenuated cholera vaccine, to protect against disease caused by Vibrio cholerae serogroup O1 in adults 18-64 years old traveling to cholera-affected areas. Vaxchora is the only cholera vaccine available in the US. A whole-cell killed injectable vaccine was previously approved, but is no longer available in the US.
      PubDate: Wed, 10 Aug 2016 11:28:00 +000
       
  • Lifitegrast (Xiidra) for Dry Eye Disease
    • Authors: admin
      Abstract: Date:  August 29, 2016 Issue #:  1502 Summary:  The FDA has approved a 5% ophthalmic solution of lifitegrast (Xiidra – Shire), a lymphocyte function-associated antigen-1 (LFA-1) antagonist, for treatment of the signs and symptoms of dry eye disease. Lifitegrast is the first LFA-1 antagonist to be approved for any indication in the US.
      PubDate: Wed, 10 Aug 2016 11:27:21 +000
       
  • AspireAssist - A New Device for Weight Loss
    • Authors: admin
      Abstract: Date:  August 29, 2016 Issue #:  1502 Summary:  The FDA has approved AspireAssist (Aspire Bariatrics), a weight-loss device that permits patients to drain a portion of their stomach contents through a gastrostomy tube into a toilet after each meal. It is approved for long-term use in combination with lifestyle modifications in adults ≥22 years old who have a body mass index (BMI) of 35 to 55 and have not been able to achieve and maintain weight loss with nonsurgical therapy.
      PubDate: Wed, 27 Jul 2016 12:19:35 +000
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2016